Fig. 1

Blinatumomab enhances RTX-mediated NK cell response. PBMCs depleted of CD3⁺ T cells were cocultured with Raji cells and RTX or trastuzumab (TRA) as the control for 7 days. Serial dilutions (from 0.75 to 50% of PBMCs) of autologous CD3⁺ T cells were added back as was blinatumomab to select samples. NK cell response was measured on day 7. A, B RTX-mediated NK cell elimination of CD19⁺ target cells and NK cell viability increase in a T cell dose-dependent manner. These changes are enhanced by blinatumomab (1 ng/mL or 10 ng/mL) at low T cell percent from 0.75 to 6%. n = 6. C, D Lower concentrations of blinatumomab at 0.1 ng/mL or 0.01 ng/mL minimally impact on RTX-mediated NK cell ADCC or viability. n = 5. Student’s t test was used to calculate statistical significance. *p < 0.05; **p < 0.01; ***p < 0.001 indicate RTX versus RTX + blina 10 ng/mL. blina blinatumomab